AlphAIAlphAI — Financial news for AI agents
investing.comNOV 42 min read$MCRB

Seres Therapeutics Inc earnings beat by $0.01, revenue fell short of estimates

Seres Therapeutics Inc (MCRB) reported Q3 EPS of -$1.63, beating estimates by $0.01, but revenue of $590K missed expectations of $12.5M. The stock is down 59.75% over 3 months and 84.57% over 12 months, with a 'weak performance' financial health score according to InvestingPro.

Original reporting
investing.com
Published Nov 4, 2026, 12:51 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 12:57 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$MCRB
Bearish
medium confidence
Mentioned
$MCRB
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$MCRBBearishLow
01

Why it matters

The earnings release shows a modest EPS beat but a severe revenue miss, likely prompting short-term price weakness.

02

Market read

Earnings miss for a microcap biotech may trigger a sell-off among risk-averse investors.

03

What to watch

Potential upcoming pipeline milestones or partnership announcements could mitigate revenue concerns.

Relevance 6/10Novelty 6/10Timing: post-market

Background

Seres Therapeutics (NASDAQ:MCRB) is a clinical-stage biotech focused on microbiome therapeutics.

Company-level read

Ticker impact

$MCRBBearishMedium confidence
Context

Seres Therapeutics reported Q3 EPS beat by $0.01 but revenue of $590K missed estimates of $12.5M, a fresh earnings disclosure.

Expected impact

downward pressure as investors price in the large revenue shortfall

Evidence & confidence

Revenue fell far short of expectations, suggesting weaker demand; EPS beat is marginal and unlikely to offset the miss.

Market effects

Sector

Biotech small-cap earnings miss may dampen sector sentiment briefly.

Regional

Limited to US biotech investors; no broader regional effect.

Global

Minimal global impact; only relevant to niche biotech investors.

Counterpoint

What could challenge this read

Some traders may view the EPS beat as a buying opportunity if the market overreacts to revenue miss.

Key entities

  • company
    Seres Therapeutics Inc

    Biotech firm reporting Q3 results.

Read at source← All news

Related articles

NOV 4
$MCRBHigh

SERES THERAPEUTICS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS AND ANNOUNCES PLANS FOR ADVANCING DEVELOPMENT OF SER-155 TO PREVENT IMMUNE CHECKPOINT…

Seres Therapeutics, Inc. (MCRB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SERES THERAPEUTICS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS AND ANNOUNCES PLANS FOR ADVANCING DEVELOPMENT OF SER-155 TO PREVENT IMMUNE CHECKPOINT INHIBITOR-RELATED ENTEROCOLITIS (irEC) Prevention approach aims to keep patients on immune checkpoint inhibitor (ICI)

SEC EDGAR 8-K2 min
OCT 15
$MCRBMed

Seres to present preclinical data on SER-428 at IDWeek 2026

Seres Therapeutics (MCRB) will present preclinical data on SER-428, an investigational oral liquid live biotherapeutic, at IDWeek 2026. SER-428 aims to reduce bloodstream infections in high-risk patients post-sepsis. Preclinical results show significant reduction in pathogens. The company plans a Phase 1b trial, pending funding. Development is supported by CARB-X.

investing.com2 min
AUG 5
$MCRBMed

SERES THERAPEUTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES, INCLUDING FURTHER ACTION TO REDUCE ONGOING FACILITIES COSTS

Seres Therapeutics, Inc. (MCRB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SERES THERAPEUTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES, INCLUDING FURTHER ACTION TO REDUCE ONGOING FACILITIES COSTS Recently announced 80% of SER-155 recipients achieved immunosuppressive-free clinical response at day 15 for im

SEC EDGAR 8-K6 min